Ibrahim Turkoz, PhD

  • 10Articles
  • 67.2KReads
  • 2004–2023Active
  • 51Collaborators
  • 205Citations

About

Ibrahim Turkoz, PhD, is affiliated with Janssen Research & Development, LLC, Titusville, New Jersey. From 2004 to 2023, Turkoz has published extensively on clinical topics including schizophrenia, schizoaffective disorders, bipolar disorder, major depressive disorder, neurology, and weight management. His work focuses on pharmacological treatments such as long-acting injectable paliperidone palmitate, esketamine nasal spray, and risperidone, as well as methodological issues in comparative antipsychotic studies and behavioral therapy effects. Frequent collaborators include Cynthia A. Bossie, Carla M. Canuso, Georges M. Gharabawi, Jean-Pierre Lindenmayer, and Larry Alphs.

Publications

JCP
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
Original Research

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

September 25, 2023

Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
, , , et al
JCP
Original Research

Response to Esketamine After Initial Nonresponse

July 20, 2021

Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate...
, , , et al
JCP
Original Research

Half-Life After Antipsychotic Discontinuation

August 23, 2017

Read the results on whether a longer half-life is associated with longer time to relapse after antipsychotic discontinuation, even among LAI formulations.
, , , et al
JCP
Original Research

Paliperidone Palmitate Once-Monthly Reduces Risk of Relapse of Psychotic, Depressive, and Manic Symptoms and Maintains Functioning in a Double-Blind, Randomized Study of Schizoaffective Disorder

December 5, 2014

, , , et al
JCP
Letter to the Editor

Cost and Cost-Effectiveness in a Randomized Trial of Long-Acting Risperidone for Schizophrenia

October 15, 2012

, , , et al
JCP
Original Research

A Randomized, Double-Blind, Placebo-Controlled Study of 2 Dose Ranges of Paliperidone Extended-Release in the Treatment of Subjects With Schizoaffective Disorder

May 15, 2010

, , , et al
JCP
Original Research

A 1-Year Double-Blind Study of 2 Doses of Long-Acting Risperidone in Stable Patients With Schizophrenia or Schizoaffective Disorder.

August 15, 2006

, , , et al
JCP
Letter to the Editor

Methodological Issues in a Comparative Study of Ziprasidone and Risperidone

January 16, 2006

, , , et al
JCP
Original Research

Effects of Behavioral Therapy on Weight Loss in Overweight and Obese Patients With Schizophrenia or Schizoaffective Disorder

February 15, 2005

, , , et al
JCP
Original Research

Acute Treatment of Psychotic Agitation: A Randomized Comparison of Oral Treatment With Risperidone and Lorazepam Versus Intramuscular Treatment With Haloperidol and Lorazepam

March 1, 2004

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe